Mavacamten: oHCM Treatment Outcomes
- Mavacamten (Camzyos), a cardiac myosin inhibitor, continues to demonstrate encouraging outcomes for individuals with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
- Jenkins noted that real-world results align with those observed in clinical trials such as EXPLORER and VALOR-HCM, highlighting the drug's potential in managing this condition.
- Data collected from three centers in the united Kingdom revealed that 70% to 80% of patients experienced noticeable symptomatic relief with mavacamten treatment.
Discover how mavacamten, a cardiac myosin inhibitor, is making strides in treating obstructive hypertrophic cardiomyopathy (oHCM). Recent data reveal 70-80% of patients experienced symptomatic relief with mavacamten – a significant outcome. as highlighted by William jenkins at the British Cardiovascular Society Annual Conference 2025, the drug also leads to significant reductions in left ventricular outflow tract (LVOT) gradients. While specialists must closely monitor the oHCM treatment to ensure benefits, the early success of mavacamten offers hope. Despite challenges in implementation, the drug is proving “life-changing” for those with oHCM. Read more on News Directory 3.What’s next in oHCM treatment? Discover what’s next …
Mavacamten Shows Promise in Treating Hypertrophic Cardiomyopathy
Updated June 11, 2025
Mavacamten (Camzyos), a cardiac myosin inhibitor, continues to demonstrate encouraging outcomes for individuals with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). William Jenkins,a consultant cardiologist at the Royal Infirmary of edinburgh,presented these findings at the British Cardiovascular Society Annual Conference 2025.
Jenkins noted that real-world results align with those observed in clinical trials such as EXPLORER and VALOR-HCM, highlighting the drug’s potential in managing this condition. The research underscores the importance of mavacamten in improving the lives of those affected by oHCM.
Data collected from three centers in the united Kingdom revealed that 70% to 80% of patients experienced noticeable symptomatic relief with mavacamten treatment. Furthermore, 90% of patients exhibited a significant reduction—30 mm Hg—in the left ventricular outflow tract (LVOT) gradient, a key indicator of reduced obstruction.
While initial stages of treatment necessitate intensive echocardiographic surveillance, Jenkins stated that the process becomes more manageable after the first few months. He anticipates a decreased reliance on echocardiography as clinicians gain more experience with mavacamten.
as a first-in-class therapy, mavacamten normalizes contractility, diminishes dynamic LVOT obstruction, and enhances cardiac filling pressures in HCM patients. Jenkins emphasized that hypertrophic cardiomyopathy develops gradually, often over decades. Patients may experience symptoms for an extended period before progressing to more severe complications such as abnormal heart rhythms or heart failure.
Katharine McIntosh, head of research and policy at Cardiomyopathy UK, described mavacamten as a “cause for excitement” among patients, acknowledging it as the first major cardiomyopathy-specific drug. However, she voiced concerns regarding the slow implementation of the drug’s rollout, despite its approval for National Health Service use in England, Wales, and Scotland.
McIntosh relayed findings from a recent Cardiomyopathy UK survey, indicating that patients who have accessed mavacamten report very positive experiences, describing the drug as “life changing.”
A significant challenge to widespread mavacamten use is the requirement for prescription and monitoring by specialists experienced in treating cardiomyopathies, a resource not universally available. Prescribing guidelines mandate echocardiography before and after initiating treatment, along with genetic testing for Cytochrome P450 (CYP) 2C19 to guide appropriate dosing.
“It’s at the point now where one would have thought that everyone who should be on it would be getting onto it. But that’s just not been the case,”
What’s next
Looking ahead, Jenkins highlighted the need for close early monitoring due to the risk of left ventricular systolic dysfunction, careful consideration of CYP2C19-related drug interactions, and thorough patient counseling regarding potential fetal toxicity risks.While mavacamten is generally well-tolerated, its high annual cost necessitates judicious initial use, primarily for patients with symptomatic, severe LVOT obstruction. the potential benefits of mavacamten for HCM patients without obstruction remain to be seen.